Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Microsensor Measures Intraocular Pressure in Glaucoma

By HospiMedica International staff writers
Posted on 18 Aug 2014
Print article
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
An implantable microsensor for wireless intraocular pressure (IOP) measurement allows close monitoring of patients’ disease status and glaucoma therapy success.

The Pro-IOP eye pressure measurement system consists of an implantable microsensor, an external hand held device that telemetrically transfers energy to the microsensor, and a cellular GSM module, which connects with the hand held device to transfer measurement data to a database that can be accessed by clinicians to review the disease status of the patient. Optionally, the patient can also have limited access to the data via an App, in order to review data history or communicate with the ophthalmologist.

The Pro-IOP delivers direct and real IOP, as expressed in mm Hg, which facilitates measurement without disrupting the patient’s lifestyle and without compromising the patient’s behavior. At the same time, the system discloses to clinicians real time, crucial information regarding patient specific pressure fluctuation and variability, shows if the chosen therapeutic measures work, and reports patient therapy adherence. The system is designed for easy patient use and can also be integrated into telemedicine systems for remote patient management.

The Pro-IOP eye pressure measurement system is a product of Implandata Ophthalmic Products (Hannover, Germany). The company has recently reported the successful implantation of the first patient within the ARGOS-02 clinical study, held at Augenklinik Bellevue (Kiel, Germany). In the ARGOS-02 clinical study, six eye centers in Germany are currently recruiting primary open angle glaucoma patients undergoing cataract extraction.

“So far the first results of this innovative product are very compelling,” said Prof. Detlef Uthoff, MD, medical director of Augenklinik Bellevue. “Up to date, early diagnosis and therapeutic management of the disease have been rather dissatisfying for eye doctors. But this innovation allows us for the first time to personalize and control therapy according to the specific needs of the glaucoma patient.”

Related Links:

Implandata Ophthalmic Products
Augenklinik Bellevue



Print article
JD Honigberg International
Radcal

Channels

Women's Health

view channel

Rotating Night Shift Raises Risk of Heart Disease in Women

Switching from day to night shift work is associated with a small increased risk for coronary heart disease (CHD) among women, according to a new study. Researchers at Brigham and Women's Hospital (Boston, AM, USA), Harvard Medical School (Boston, MA, USA), and other institutions conducted a prospective cohort study... Read more

Hospital News

view channel
Image: Hollywood Presbyterian Medical Center (Photo courtesy of HPMC).

Hollywood Presbyterian Launches USD 200 Million Expansion

The 100-year-old Hollywood Presbyterian Medical Center (HPMC; Los Angeles, CA, USA) is about to kick off its USD 200 million expansion and modernization of the facility. Phase one of the expansion will... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.